| 摘要 |
PROBLEM TO BE SOLVED: To provide a method and a kit for detecting a genetic factor of an appearance risk of adverse effects on treatment with an anticancer agent. SOLUTION: The method for detecting the genetic factor of the appearance risk of the adverse effects comprises analyzing one or more SNPs (single nucleotide polymorphisms) in the genome of a CYP1A1 (an estrogen metabolic enzyme) of an individual and determining the presence or absence of a mutation. The method further relates to a method for predicting the adverse effects with the anticancer agent. In the most preferred mode, the method comprises judging the onset risk of the adverse effects on digestive organ injury with EMP (estramustine phosphate sodium) to be low when the SNPs of genotypes of m1 (dbSNP:rs4646903), m2 (dbSNP:rs1048943) and/or IVS1-728 (dbSNP:rs4646421) are minor alleles in the genome of the CYP1A1. COPYRIGHT: (C)2006,JPO&NCIPI
|
